{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    7
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "02",
        "name": "Amendment 02",
        "scope": {
          "id": "b8d1b78f-bb9c-4c9e-ba13-fdd9088738a2",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "3858186d-a3d9-4643-a58c-a4ec2617b59d",
          "code": {
            "id": "b0c363dd-6fc4-4902-8153-b7ae6be16985",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "97e2944c-cde9-4da5-bb96-5e5ebc6d96f0",
            "type": {
              "id": "41f67c6c-c410-42cc-8ec6-e95483635d44",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Addition of collection of peripheral blood mononuclear cells (PBMCs) and myeloid derived suppressor cells (MDSCs) collected from subjects at baseline from selected sites, reduction of frequency of HCV RNA testing for HCV infected subjects, clarification of locoregional therapy inclusion criteria.",
        "effectiveDate": "2015-10-01",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "Revised Protocol 01"
      },
      {
        "id": "amend_2",
        "number": "11",
        "name": "Amendment 11",
        "scope": {
          "id": "a170e16e-f662-4f0e-903c-f6b1609babe2",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "a056c845-8ec4-4fe4-ac2d-59c6ab6ee451",
          "code": {
            "id": "f667d23c-2c94-490e-ba4c-c506b4c244f1",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "45f7d153-57e9-490c-8919-d561d998ddeb",
            "type": {
              "id": "7025d6e5-1cc4-46ae-9436-1b5b7a3ee71f",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Updated Study Director/Medical Monitor information; Co-primary endpoint and objective changed from time to progression (TTP) to objective response rate (ORR); Added requirement for confirmatory scan to be performed for CR/PR assessment of best overall response (BOR); Management algorithms updated per revised nivolumab IB.",
        "effectiveDate": "2016-08-24",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2",
          "ar_2_3"
        ],
        "previousVersion": "Revised Protocol 01",
        "newVersion": "Revised Protocol 02"
      },
      {
        "id": "amend_3",
        "number": "16",
        "name": "Amendment 16",
        "scope": {
          "id": "05546038-ab0e-4d2e-975c-1e9755812344",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "042fab0d-fe46-450b-b85a-fb0c6093a98c",
          "code": {
            "id": "1513fefb-3df2-4552-a77c-47bd0acbcb81",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "8bbec3f3-52d3-4392-b388-24718620872e",
            "type": {
              "id": "cf4ac764-1251-4b33-9d7c-0e9bc21fb076",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The purpose of this amendment is to change Overall Response Rate (ORR) from a co-primary objective to a secondary objective of the study. Overall Survival (OS) will be the sole Primary Endpoint of the study.",
        "effectiveDate": "2017-08-15",
        "reasonIds": [
          "ar_3_1",
          "ar_3_2"
        ],
        "previousVersion": "Revised Protocol 02",
        "newVersion": "Revised Protocol 03"
      },
      {
        "id": "amend_4",
        "number": "18",
        "name": "Amendment 18",
        "scope": {
          "id": "cc6ae08d-abab-4260-bf5e-4f4a57e0340c",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "1a57f7f2-fb09-48b8-a66b-cce5258b3f59",
          "code": {
            "id": "82b4f728-3e9b-4447-80c1-82bf8a6d09ca",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "378fefdd-bcc8-41ca-b772-d5db409b3aba",
            "type": {
              "id": "fbf40d2f-b7e5-4560-ae00-7a34825ced2b",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary reason for this amendment is to update several protocol sections to reflect the most recent guidance for treating study participants with nivolumab. In addition, an exploratory objective evaluating the correlation of tumor inflammation with efficacy based on recent preliminary data has been added. Several minor inconsistencies in study objectives and endpoints and minor administrative changes are also addressed.",
        "effectiveDate": "2019-01-15",
        "reasonIds": [
          "ar_4_1",
          "ar_4_2",
          "ar_4_3"
        ],
        "previousVersion": "Revised Protocol 03",
        "newVersion": "Revised Protocol 04"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_3",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_2",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_3",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [],
    "studySites": [],
    "summary": {
      "amendmentCount": 4,
      "countryCount": 0,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "regions": [
        "Asia",
        "Non-Asia"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "02",
        "effectiveDate": "2015-10-01",
        "summary": "Addition of collection of peripheral blood mononuclear cells (PBMCs) and myeloid derived suppressor cells (MDSCs) collected from subjects at baseline from selected sites, reduction of frequency of HCV RNA testing for HCV infected subjects, clarification of locoregional therapy inclusion criteria.",
        "previousVersion": "Original Protocol",
        "newVersion": "Revised Protocol 01",
        "reasons": [
          "Scientific",
          "Operational"
        ]
      },
      {
        "number": "11",
        "effectiveDate": "2016-08-24",
        "summary": "Updated Study Director/Medical Monitor information; Co-primary endpoint and objective changed from time to progression (TTP) to objective response rate (ORR); Added requirement for confirmatory scan to be performed for CR/PR assessment of best overall response (BOR); Management algorithms updated per revised nivolumab IB.",
        "previousVersion": "Revised Protocol 01",
        "newVersion": "Revised Protocol 02",
        "reasons": [
          "Scientific",
          "Safety",
          "Administrative"
        ]
      },
      {
        "number": "16",
        "effectiveDate": "2017-08-15",
        "summary": "The purpose of this amendment is to change Overall Response Rate (ORR) from a co-primary objective to a secondary objective of the study. Overall Survival (OS) will be the sole Primary Endpoint of the study.",
        "previousVersion": "Revised Protocol 02",
        "newVersion": "Revised Protocol 03",
        "reasons": [
          "Scientific",
          "Regulatory"
        ]
      },
      {
        "number": "18",
        "effectiveDate": "2019-01-15",
        "summary": "The primary reason for this amendment is to update several protocol sections to reflect the most recent guidance for treating study participants with nivolumab. In addition, an exploratory objective evaluating the correlation of tumor inflammation with efficacy based on recent preliminary data has been added. Several minor inconsistencies in study objectives and endpoints and minor administrative changes are also addressed.",
        "previousVersion": "Revised Protocol 03",
        "newVersion": "Revised Protocol 04",
        "reasons": [
          "Safety",
          "Scientific",
          "Administrative"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [],
      "regions": [
        "Asia",
        "Non-Asia"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}